quinoxalines has been researched along with Depressive Disorder in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 5 (23.81) | 29.6817 |
| 2010's | 11 (52.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pałucha-Poniewiera, A; Pilc, A; Podkowa, K | 1 |
| Devadoss, T; Gupta, D; Kurhe, Y; Radhakrishnan, M | 1 |
| Ditre, JW; Farris, SG; Leventhal, AM; Schmidt, NB; Zvolensky, MJ | 1 |
| Gupta, D; Radhakrishnan, M; Thangaraj, D | 1 |
| Lenda, T; Pałucha-Poniewiera, A; Pilc, A; Podkowa, A; Podkowa, K; Sałat, K | 1 |
| Devadoss, T; Mahesh, R; Modak, N; Pandey, DK | 1 |
| Anderson, WH; Catlow, JT; Felder, CC; Higgs, RE; Kuo, MS; Laksmanan, A; Li, X; Martin, AE; Nikolayev, A; Schober, DA; Tolstikov, VV; Witkin, JM | 1 |
| Nelson, R; Pumariega, AJ; Rotenberg, L | 1 |
| Dybała, M; Nowak, G; Pilc, A; Poleszak, E; Siwek, A | 1 |
| Catz, SL; Deprey, M; Jack, L; Javitz, H; McAfee, TA; McClure, JB; Richards, J; Swan, GE; Zbikowski, SM | 1 |
| Carpenter, LL; Philip, NS; Price, LH; Tyrka, AR; Whiteley, LB | 1 |
| Diehl, A; Grosshans, M; Hermann, D; Mann, K; Mutschler, J | 1 |
| Baran, XY; Docherty, JP | 1 |
| Mineur, YS; Picciotto, MR | 1 |
| Guwanardane, N; Hussain, S; Kayne, E; Petrides, G | 1 |
| Argo, T; Cantrell, M; Haak, L; Janney, L | 1 |
| Honda, K; Kaneko, M; Kanno, T; Kumashiro, H; Mashiko, H; Oosuga, N; Watanabe, A | 1 |
| Barturen, F; García-Sevilla, JA; Meana, JJ | 1 |
| Bovier, P; Gaillard, JM; Karege, F; Tissot, R; Widmer, J | 1 |
| Healy, D; Horton, RW; Kerry, SM; Lawrence, KM; Paykel, ES; Theodorou, AE; White, W; Whitehouse, AM; Wilton-Cox, H | 1 |
| Areso, P; García-Sevilla, JA; Giralt, MT; Guimón, J; Padró, D | 1 |
1 review(s) available for quinoxalines and Depressive Disorder
| Article | Year |
|---|---|
Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis.
Topics: Acetylcholine; Animals; Antidepressive Agents; Benzazepines; Depressive Disorder; Drug Partial Agonism; Humans; Nicotinic Agonists; Nicotinic Antagonists; Quinoxalines; Receptors, Cholinergic; Self Medication; Signal Transduction; Suicidal Ideation; Tobacco Use Disorder; Varenicline | 2010 |
1 trial(s) available for quinoxalines and Depressive Disorder
| Article | Year |
|---|---|
Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline.
Topics: Adult; Affect; Benzazepines; Depressive Disorder; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mood Disorders; Quinoxalines; Smoking; Smoking Cessation; Varenicline | 2009 |
19 other study(ies) available for quinoxalines and Depressive Disorder
| Article | Year |
|---|---|
Role of AMPA receptor stimulation and TrkB signaling in the antidepressant-like effect of ketamine co-administered with a group II mGlu receptor antagonist, LY341495, in the forced swim test in rats.
Topics: Amino Acids; Animals; Antidepressive Agents; Azepines; Benzamides; Depression; Depressive Disorder; Excitatory Amino Acid Antagonists; Ketamine; Male; Prefrontal Cortex; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptor, trkB; Receptors, AMPA; Receptors, Metabotropic Glutamate; Signal Transduction; Xanthenes | 2019 |
QCM-4 a novel 5-HT3 antagonist attenuates the behavioral and biochemical alterations on chronic unpredictable mild stress model of depression in Swiss albino mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain; Catalase; Depressive Disorder; Glutathione; Lipid Peroxidation; Male; Mice; Motor Activity; Nitrites; Quinoxalines; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Stress, Physiological; Superoxide Dismutase | 2014 |
Emotional disorders and smoking: relations to quit attempts and cessation strategies among treatment-seeking smokers.
Topics: Adult; Anxiety Disorders; Benzazepines; Bupropion; Cross-Sectional Studies; Depressive Disorder; Dopamine Uptake Inhibitors; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline; Young Adult | 2015 |
A novel 5HT3 antagonist 4i (N-(3-chloro-2-methylphenyl)quinoxalin-2-carboxamide) prevents diabetes-induced depressive phenotypes in mice: Modulation of serotonergic system.
Topics: Animals; Antidepressive Agents; Biguanides; Brain; Depressive Disorder; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fluoxetine; Male; Mice; Quinoxalines; Random Allocation; Receptors, Serotonin, 5-HT3; Serotonin; Serotonin 5-HT3 Receptor Agonists; Serotonin 5-HT3 Receptor Antagonists | 2016 |
Antidepressant-like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495.
Topics: Amino Acids; Animals; Antidepressive Agents; Depressive Disorder; Excitatory Amino Acid Antagonists; Male; Maze Learning; Mice; Mice, Inbred C57BL; Motor Activity; Prefrontal Cortex; Quinoxalines; Receptors, AMPA; Receptors, Metabotropic Glutamate; Scopolamine; Serotonin; Xanthenes | 2016 |
Antidepressant & anxiolytic activities of N-(pyridin-3-yl) quinoxalin-2-carboxamide: A novel serotonin type 3 receptor antagonist in behavioural animal models.
Topics: Animals; Antidepressive Agents; Anxiety; Depression; Depressive Disorder; Disease Models, Animal; Feeding and Eating Disorders; Male; Mice; Motor Activity; Obsessive-Compulsive Disorder; Quinoxalines; Rats; Rats, Wistar; Receptors, Serotonin; Schizophrenia; Serotonin; Serotonin 5-HT3 Receptor Antagonists | 2016 |
Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice.
Topics: Animals; Antidepressive Agents; Citalopram; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Frontal Lobe; Ketamine; Male; Metabolome; Mice, Inbred C57BL; Mice, Knockout; Morpholines; Quinoxalines; Receptor, Muscarinic M1; Receptors, AMPA; Scopolamine; Selective Serotonin Reuptake Inhibitors; TOR Serine-Threonine Kinases | 2017 |
Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression.
Topics: Antipsychotic Agents; Aripiprazole; Benzazepines; Bipolar Disorder; Depressive Disorder; Female; Genetic Predisposition to Disease; Humans; Middle Aged; Piperazines; Psychoses, Substance-Induced; Psychotherapy; Quinolones; Quinoxalines; Smoking Cessation; Stress, Psychological; Varenicline | 2008 |
Lack of NMDA-AMPA interaction in antidepressant-like effect of CGP 37849, an antagonist of NMDA receptor, in the forced swim test.
Topics: 2-Amino-5-phosphonovalerate; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Depressive Disorder; Excitatory Amino Acid Antagonists; Mice; Motor Activity; N-Methylaspartate; Quinoxalines; Receptors, N-Methyl-D-Aspartate; Swimming | 2008 |
Varenicline augmentation in depressed smokers: an 8-week, open-label study.
Topics: Adolescent; Adult; Aged; Benzazepines; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Personality Inventory; Psychotropic Drugs; Quinoxalines; Receptors, Nicotinic; Severity of Illness Index; Smoking Cessation; Smoking Prevention; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2009 |
Reduced affective symptoms during tobacco dependence treatment with varenicline.
Topics: Affective Symptoms; Benzazepines; Depressive Disorder; Female; Humans; Middle Aged; Nicotinic Agonists; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2009 |
Rapid and sustained response to a single dose of sertraline in a patient with newly emergent depression during varenicline-assisted smoking cessation.
Topics: Adult; Antidepressive Agents; Benzazepines; Depressive Disorder; Humans; Male; Quinoxalines; Sertraline; Smoking Cessation; Varenicline | 2010 |
Varenicline induced mania in a 51 year old patient without history of bipolar illness.
Topics: Benzazepines; Bipolar Disorder; Depressive Disorder; Humans; Male; Middle Aged; Nicotinic Agonists; Paranoid Disorders; Patient Admission; Quinoxalines; Smoking Cessation; Varenicline | 2011 |
Adverse neuropsychiatric events associated with varenicline use in veterans: a case series.
Topics: Adult; Benzazepines; Bipolar Disorder; Comorbidity; Depressive Disorder; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Stress Disorders, Post-Traumatic; Suicidal Ideation; Tobacco Use Disorder; United States; Varenicline; Veterans | 2012 |
Platelet alpha-2 adrenergic receptor binding and plasma free 3-methoxy-4-hydroxyphenylethylene glycol in depressed patients before and after treatment with mianserin.
Topics: Aged; Biomarkers; Blood Platelets; Brimonidine Tartrate; Depressive Disorder; Female; Humans; Ligands; Male; Methoxyhydroxyphenylglycol; Mianserin; Psychiatric Status Rating Scales; Quinoxalines; Receptors, Adrenergic, alpha | 1992 |
Alpha 2-adrenoceptors in the brain of suicide victims: increased receptor density associated with major depression.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Binding, Competitive; Brain; Brain Mapping; Brimonidine Tartrate; Clonidine; Depressive Disorder; Female; Humans; Male; Middle Aged; Quinoxalines; Radioligand Assay; Receptors, Adrenergic; Schizophrenia; Schizophrenic Psychology; Suicide; Violence | 1992 |
Platelet membrane alpha 2-adrenergic receptors in depression.
Topics: Adrenergic alpha-Agonists; Adult; Antidepressive Agents; Bipolar Disorder; Blood Platelets; Brimonidine Tartrate; Depressive Disorder; Female; Follow-Up Studies; Humans; Magnesium; Male; Methoxyhydroxyphenylglycol; Middle Aged; Quinoxalines; Radioligand Assay; Receptors, Adrenergic | 1992 |
Platelet alpha 2-adrenoceptors, defined with agonist and antagonist ligands, in depressed patients, prior to and following treatment.
Topics: Adrenergic alpha-Agonists; Binding, Competitive; Blood Platelets; Brimonidine Tartrate; Depressive Disorder; Electroconvulsive Therapy; Humans; Imipramine; Lofepramine; Psychiatric Status Rating Scales; Quinoxalines; Radioligand Assay; Receptors, Adrenergic; Yohimbine | 1991 |
Alpha 2-adrenoceptor-mediated inhibition of platelet adenylate cyclase and induction of aggregation in major depression. Effect of long-term cyclic antidepressant drug treatment.
Topics: Adenylyl Cyclase Inhibitors; Adrenergic alpha-Agonists; Adult; Aged; Antidepressive Agents, Tricyclic; Blood Platelets; Brimonidine Tartrate; Colforsin; Depressive Disorder; Epinephrine; Female; Humans; Male; Middle Aged; Platelet Aggregation; Quinoxalines; Receptors, Adrenergic, alpha | 1990 |